Indaptus Therapeutics (INDP) Expected to Announce Quarterly Earnings on Thursday

Indaptus Therapeutics (NASDAQ:INDP) is anticipated to post its results before the market opens on Thursday, March 12th. Analysts expect Indaptus Therapeutics to post earnings of ($4.36) per share for the quarter.

Indaptus Therapeutics Price Performance

Indaptus Therapeutics stock opened at $1.87 on Wednesday. The business has a 50-day simple moving average of $2.30 and a two-hundred day simple moving average of $2.86. Indaptus Therapeutics has a 52-week low of $1.52 and a 52-week high of $47.60. The company has a market cap of $4.19 million, a P/E ratio of -0.06 and a beta of 0.97.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on INDP. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Indaptus Therapeutics in a report on Thursday, January 22nd. Wall Street Zen downgraded shares of Indaptus Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.